Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis

Phase 1 trial outcomes

Eva L. Feldman, Nicholas M. Boulis, Junguk Hur, Karl Johe, Seward B. Rutkove, Thais Federici, Meraida Polak, Jane Bordeau, Stacey A. Sakowski, Jonathan D. Glass

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

Objective The US Food and Drug Administration-approved trial, "A Phase 1, Open-Label, First-in-Human, Feasibility and Safety Study of Human Spinal Cord-Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis, Protocol Number: NS2008-1," is complete. Our overall objective was to assess the safety and feasibility of stem cell transplantation into lumbar and/or cervical spinal cord regions in amyotrophic lateral sclerosis (ALS) subjects. Methods Preliminary results have been reported on the initial trial cohort of 12 ALS subjects. Here, we describe the safety and functional outcome monitoring results for the final trial cohort, consisting of 6 ALS subjects receiving 5 unilateral cervical intraspinal neural stem cell injections. Three of these subjects previously received 10 total bilateral lumbar injections as part of the earlier trial cohort. All injections utilized a novel spinal-mounted stabilization and injection device to deliver 100,000 neural stem cells per injection, for a dosing range up to 1.5 million cells. Subject assessments included detailed pre- and postsurgical neurological outcome measures. Results The cervical injection procedure was well tolerated and disease progression did not accelerate in any subject, verifying the safety and feasibility of cervical and dual-targeting approaches. Analyses on outcome data revealed preliminary insight into potential windows of stem cell biological activity and identified clinical assessment measures that closely correlate with ALS Functional Rating Scale-Revised scores, a standard assessment for ALS clinical trials. Interpretation This is the first report of cervical and dual-targeted intraspinal transplantation of neural stem cells in ALS subjects. This approach is feasible and well-tolerated, supporting future trial phases examining therapeutic dosing and efficacy. Ann Neurol 2014;75:363-373

Original languageEnglish (US)
Pages (from-to)363-373
Number of pages11
JournalAnnals of Neurology
Volume75
Issue number3
DOIs
StatePublished - Jan 1 2014

Fingerprint

Neural Stem Cells
Amyotrophic Lateral Sclerosis
Stem Cell Transplantation
Injections
Safety
Feasibility Studies
United States Food and Drug Administration
Disease Progression
Amyotrophic lateral sclerosis 1
Spinal Cord
Stem Cells
Transplantation
Outcome Assessment (Health Care)
Clinical Trials
Equipment and Supplies
Therapeutics

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Feldman, E. L., Boulis, N. M., Hur, J., Johe, K., Rutkove, S. B., Federici, T., ... Glass, J. D. (2014). Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: Phase 1 trial outcomes. Annals of Neurology, 75(3), 363-373. https://doi.org/10.1002/ana.24113

Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis : Phase 1 trial outcomes. / Feldman, Eva L.; Boulis, Nicholas M.; Hur, Junguk; Johe, Karl; Rutkove, Seward B.; Federici, Thais; Polak, Meraida; Bordeau, Jane; Sakowski, Stacey A.; Glass, Jonathan D.

In: Annals of Neurology, Vol. 75, No. 3, 01.01.2014, p. 363-373.

Research output: Contribution to journalArticle

Feldman, EL, Boulis, NM, Hur, J, Johe, K, Rutkove, SB, Federici, T, Polak, M, Bordeau, J, Sakowski, SA & Glass, JD 2014, 'Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: Phase 1 trial outcomes', Annals of Neurology, vol. 75, no. 3, pp. 363-373. https://doi.org/10.1002/ana.24113
Feldman, Eva L. ; Boulis, Nicholas M. ; Hur, Junguk ; Johe, Karl ; Rutkove, Seward B. ; Federici, Thais ; Polak, Meraida ; Bordeau, Jane ; Sakowski, Stacey A. ; Glass, Jonathan D. / Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis : Phase 1 trial outcomes. In: Annals of Neurology. 2014 ; Vol. 75, No. 3. pp. 363-373.
@article{d9de039d53ca4a71987fc547c638c50e,
title = "Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: Phase 1 trial outcomes",
abstract = "Objective The US Food and Drug Administration-approved trial, {"}A Phase 1, Open-Label, First-in-Human, Feasibility and Safety Study of Human Spinal Cord-Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis, Protocol Number: NS2008-1,{"} is complete. Our overall objective was to assess the safety and feasibility of stem cell transplantation into lumbar and/or cervical spinal cord regions in amyotrophic lateral sclerosis (ALS) subjects. Methods Preliminary results have been reported on the initial trial cohort of 12 ALS subjects. Here, we describe the safety and functional outcome monitoring results for the final trial cohort, consisting of 6 ALS subjects receiving 5 unilateral cervical intraspinal neural stem cell injections. Three of these subjects previously received 10 total bilateral lumbar injections as part of the earlier trial cohort. All injections utilized a novel spinal-mounted stabilization and injection device to deliver 100,000 neural stem cells per injection, for a dosing range up to 1.5 million cells. Subject assessments included detailed pre- and postsurgical neurological outcome measures. Results The cervical injection procedure was well tolerated and disease progression did not accelerate in any subject, verifying the safety and feasibility of cervical and dual-targeting approaches. Analyses on outcome data revealed preliminary insight into potential windows of stem cell biological activity and identified clinical assessment measures that closely correlate with ALS Functional Rating Scale-Revised scores, a standard assessment for ALS clinical trials. Interpretation This is the first report of cervical and dual-targeted intraspinal transplantation of neural stem cells in ALS subjects. This approach is feasible and well-tolerated, supporting future trial phases examining therapeutic dosing and efficacy. Ann Neurol 2014;75:363-373",
author = "Feldman, {Eva L.} and Boulis, {Nicholas M.} and Junguk Hur and Karl Johe and Rutkove, {Seward B.} and Thais Federici and Meraida Polak and Jane Bordeau and Sakowski, {Stacey A.} and Glass, {Jonathan D.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1002/ana.24113",
language = "English (US)",
volume = "75",
pages = "363--373",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis

T2 - Phase 1 trial outcomes

AU - Feldman, Eva L.

AU - Boulis, Nicholas M.

AU - Hur, Junguk

AU - Johe, Karl

AU - Rutkove, Seward B.

AU - Federici, Thais

AU - Polak, Meraida

AU - Bordeau, Jane

AU - Sakowski, Stacey A.

AU - Glass, Jonathan D.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objective The US Food and Drug Administration-approved trial, "A Phase 1, Open-Label, First-in-Human, Feasibility and Safety Study of Human Spinal Cord-Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis, Protocol Number: NS2008-1," is complete. Our overall objective was to assess the safety and feasibility of stem cell transplantation into lumbar and/or cervical spinal cord regions in amyotrophic lateral sclerosis (ALS) subjects. Methods Preliminary results have been reported on the initial trial cohort of 12 ALS subjects. Here, we describe the safety and functional outcome monitoring results for the final trial cohort, consisting of 6 ALS subjects receiving 5 unilateral cervical intraspinal neural stem cell injections. Three of these subjects previously received 10 total bilateral lumbar injections as part of the earlier trial cohort. All injections utilized a novel spinal-mounted stabilization and injection device to deliver 100,000 neural stem cells per injection, for a dosing range up to 1.5 million cells. Subject assessments included detailed pre- and postsurgical neurological outcome measures. Results The cervical injection procedure was well tolerated and disease progression did not accelerate in any subject, verifying the safety and feasibility of cervical and dual-targeting approaches. Analyses on outcome data revealed preliminary insight into potential windows of stem cell biological activity and identified clinical assessment measures that closely correlate with ALS Functional Rating Scale-Revised scores, a standard assessment for ALS clinical trials. Interpretation This is the first report of cervical and dual-targeted intraspinal transplantation of neural stem cells in ALS subjects. This approach is feasible and well-tolerated, supporting future trial phases examining therapeutic dosing and efficacy. Ann Neurol 2014;75:363-373

AB - Objective The US Food and Drug Administration-approved trial, "A Phase 1, Open-Label, First-in-Human, Feasibility and Safety Study of Human Spinal Cord-Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis, Protocol Number: NS2008-1," is complete. Our overall objective was to assess the safety and feasibility of stem cell transplantation into lumbar and/or cervical spinal cord regions in amyotrophic lateral sclerosis (ALS) subjects. Methods Preliminary results have been reported on the initial trial cohort of 12 ALS subjects. Here, we describe the safety and functional outcome monitoring results for the final trial cohort, consisting of 6 ALS subjects receiving 5 unilateral cervical intraspinal neural stem cell injections. Three of these subjects previously received 10 total bilateral lumbar injections as part of the earlier trial cohort. All injections utilized a novel spinal-mounted stabilization and injection device to deliver 100,000 neural stem cells per injection, for a dosing range up to 1.5 million cells. Subject assessments included detailed pre- and postsurgical neurological outcome measures. Results The cervical injection procedure was well tolerated and disease progression did not accelerate in any subject, verifying the safety and feasibility of cervical and dual-targeting approaches. Analyses on outcome data revealed preliminary insight into potential windows of stem cell biological activity and identified clinical assessment measures that closely correlate with ALS Functional Rating Scale-Revised scores, a standard assessment for ALS clinical trials. Interpretation This is the first report of cervical and dual-targeted intraspinal transplantation of neural stem cells in ALS subjects. This approach is feasible and well-tolerated, supporting future trial phases examining therapeutic dosing and efficacy. Ann Neurol 2014;75:363-373

UR - http://www.scopus.com/inward/record.url?scp=84897997188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897997188&partnerID=8YFLogxK

U2 - 10.1002/ana.24113

DO - 10.1002/ana.24113

M3 - Article

VL - 75

SP - 363

EP - 373

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 3

ER -